Here's a forgotten one , they still don't sell in China so maybe its still in play ? S3 Investment Company Subsidiary SINO UJE Receives Distribution Rights to Medical Diagnostic Testing Products in China Market
Issued Wednesday July 19, 10:30 am ET
TEMECULA, CA -- (MARKET WIRE) -- Jul 19, 2006 -- S3 Investment Company, Inc. (OTC BB: SEIH) today announced that subsidiary SINO UJE, Ltd. has been awarded distribution rights in China to the HandiLab line of medical diagnostic tests from Zonda Incorporated, a California based company. The HandiLab line of tests includes innovative, rapid, self-contained diagnostic devices for the detection of chlamydia, gonorrhea, yeast (Candida albicans) and group A Strep.
The agreement covers the process of gaining State Food and Drug Administration (SFDA) approval for HandiLab products, the development of marketing strategies, and their integration into SINO UJE’s distribution network.
Zonda’s HandiLab products are currently distributed in approximately 18 countries in Europe, where they carry the CE mark, which signifies that the product complies with the relevant health, safety, environmental protection requirements and can therefore be legally placed on the market. The HandiLab-C test is the only over-the-counter test (self testing) for chlamydia that has received the CE mark.
“This agreement brings SINO UJE a highly sought-after line of medical products for distribution - this one in the growing infectious disease testing market for which there is an expanding demand around the world,” stated Jim Bickel, chief executive officer of S3. “The HandiLab tests, much like For Life’s Stomocur devices, are disposables, which provides SINO UJE with more products that must be reordered on a regular basis, generating greater revenues for both the supplier and SINO UJE as the distributor. We expect that these types of products will contribute to growing revenues streams as S3 begins to report consolidated financial information on its subsidiaries in upcoming financial filings.
